Navigation Links
FDA's New Safety Controls for LABA-Containing Drugs Will Impact Prescribing of Single-Agent ICS and LABA/ICS Combination Therapies for the Treatment of Asthma
Date:8/24/2010

WALTHAM, Mass., Aug. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that some surveyed physicians indicate that they will decrease their overall prescribing of long-acting beta2 agonists (LABA)/inhaled corticosteroids (ICS) combination therapies over the next 12 months for the treatment of asthma in response to the U.S. Food and Drug Administration's new safety controls for LABA-containing medications. Most notably, the FDA controls state that LABA/ICS combination medications should be reserved for patients who remain uncontrolled despite treatment with controller medications (e.g., single-agent ICS therapies).

According to the new report entitled Treatment Algorithms in Asthma, more than 40 percent of surveyed physicians report that they will decrease their prescribing of LABA/ICS combinations prior to attempting treatment with a single-agent ICS drug over the next 12 months.

While surveyed physicians indicate that the FDA controls for LABA-containing drugs will affect their decision to prescribe a LABA/ICS combination therapy prior to attempting treatment with a single-agent ICS, surveyed physicians also report that first-line prescribing of LABA/ICS combinations remains common. In particular, surveyed physicians are most likely to prescribe a LABA/ICS combination, such as GlaxoSmithKline's Advair or AstraZeneca's Symbicort, as a first-line maintenance therapy for newly diagnosed adult patients with moderate or severe persistent asthma.

"Some surveyed physicians say they will decrease their use of LABA/ICS combination medications for the treatment of asthma, a trend that may have positive implications for the single-agent ICS class of therapies," said Decision Resources Analyst Martin Quinn. "As a result, marketers of LABA/ICS combination medications and single-agent ICS therapies must focus not only on competitive dyna
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
9. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 15, 2014  Colorado and ... have legalized adult use of cannabis. Oregon ... D.C. ended prohibition during the November 2014 elections. ... Photo - http://photos.prnewswire.com/prnh/20141212/164153LOGO The benefits ... noted and obvious benefits like the increased tax revenue for ...
(Date:12/15/2014)... 2014   DaVita HealthCare Partners Inc.  (NYSE: ... largest and most innovative health care communities, today ... DaVita Clinical Research  (DCR) and  HealthCare Partners Clinical Research ... extensive clinical research and data analytics services, specifically ... end-stage renal disease (ESRD), as well as primary ...
(Date:12/13/2014)... 11, 2014 Research and Markets ... the "Drug Injection Devices to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769 As new drugs ... list of health conditions, drug developers have increasingly ... administration process and increase the efficiency and reliability ...
Breaking Medicine Technology:CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4
... ( US HIFU ), a world leader in minimally invasive ... ) technologies and manufacturer of the Sonablate® 500 medical device ... available to prostate cancer patients for the first ... Curitiba, capital city of the state of Parana in southern ...
... Medical, Inc. ("Kips Bay"), a development stage medical device ... vein support technology, or eSVS MESH, for use in ... it has closed its previously announced offering of 2,062,500 ... $8.00 per share.   Kips Bay ...
Cached Medicine Technology:Sonablate® HIFU for Prostate Cancer in New Locations Outside the U.S. 2Sonablate® HIFU for Prostate Cancer in New Locations Outside the U.S. 3Sonablate® HIFU for Prostate Cancer in New Locations Outside the U.S. 4Kips Bay Medical Announces Closing of its $16.5 Million Initial Public Offering of Common Stock 2
(Date:12/15/2014)... Cancer researchers have just published an important new report ... pleural mesothelioma. Surviving Mesothelioma has just posted an article ... to read it now. , Doctors at Harvard, ... York’s Langone Medical Center performed complete genetic analyses on ... effort to pinpoint the genes that are most likely ...
(Date:12/15/2014)... SIMpalm, a leading mobile app development company , ... client, which allows users to keep track of wines ... the right wine. At the center of WineMatch ... and wine information. All this information is assembled to ... that are close counterparts to one another are called ...
(Date:12/15/2014)... 14, 2014 (HealthDay News) -- Expert pilots process visual ... why they make better decisions during landings, a new ... difficult techniques for pilots to master, and 36 percent ... crashes occur during final approach and landing. Researchers ... 12 moderately experienced pilots while they were at the ...
(Date:12/15/2014)... In support of high-quality independent peer ... state laws that may have unintended consequences through ... of public health policy. , The position paper, ... Independent Review, contends that state legislation that restricts ... determinations can result in subpar outcomes for both ...
(Date:12/15/2014)... For the second year in a row, Bird Rock ... 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak came in ... 10. This is the first year that any roaster made ... on quality, value, and other aspects, including certifications and distinct ... and at $17.99 for 12-ounces, was also the most affordable ...
Breaking Medicine News(10 mins):Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... Calif., March 26 Endocare, Inc.,(Nasdaq: ENDO ), ... minimally invasive technologies for tissue and tumor,ablation, today announced ... the B. Riley & Co. 9th Annual Las Vegas ... Friday, April 4, 2008. The conference is,being held at ...
... CAMPAIGN KICKS OFF TODAY, LOS ANGELES, March 26 ... the American Academy of Neurology,(AAN), the American College of ... is raising awareness about the warning signs,of stroke and ... a campaign called "Give Me 5: Walk, Talk, Reach, ...
... LOUIS, March 25 KV Pharmaceutical Company,(NYSE: ... that,develops, manufactures, acquires and markets technology differentiated,branded ... of its fiscal 2007 Form 10-K with ... includes restatements of previously reported results for,fiscal ...
... 25 As Americans get a "wake-up call",about ... men with type 2,diabetes to know that they ... men., Listen to this report from Solvay ... access video, audio, text, graphics and,photos for free ...
... March 25 Author and Patient,Advocate Teri Robert ... --,she,s been experiencing headaches and migraine attacks herself ... help those in,the migraine community, Robert, in conjunction ... the launch of the,"Putting Our Heads Together" Poetry ...
... COLUMBUS, Ohio A new study reviewing 75 group-randomized ... than half of those studies used appropriate statistical methods ... trials may have reported that interventions to prevent disease ... they might not have been. , More than a ...
Cached Medicine News:Health News:Endocare to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference 2Health News:Morgan Fairchild Joins Neurologists, Emergency Physicians and the American Stroke Association to Educate the Public About Stroke Symptoms 2Health News:Morgan Fairchild Joins Neurologists, Emergency Physicians and the American Stroke Association to Educate the Public About Stroke Symptoms 3Health News:Morgan Fairchild Joins Neurologists, Emergency Physicians and the American Stroke Association to Educate the Public About Stroke Symptoms 4Health News:KV Pharmaceutical Company Completes Financial Restatement with the Filing of Fiscal 2007 Form 10-K 2Health News:KV Pharmaceutical Company Completes Financial Restatement with the Filing of Fiscal 2007 Form 10-K 3Health News:KV Pharmaceutical Company Completes Financial Restatement with the Filing of Fiscal 2007 Form 10-K 4Health News:MyMigraineConnection.com and Migraine Expert Teri Robert Announce Seventh Annual Migraine and Headache Poetry Contest 2Health News:MyMigraineConnection.com and Migraine Expert Teri Robert Announce Seventh Annual Migraine and Headache Poetry Contest 3Health News:Review of group-based cancer trials reveals flaws in studies' design and analysis 2Health News:Review of group-based cancer trials reveals flaws in studies' design and analysis 3
This cannula is flanged with radiopaque tip with 2 side holes....
This cannula features a PVC body, auto inflatable smooth cuff, pressure monitoring line with integral stopcock....
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
The DLP Elongated One-Piece Arterial Cannulae features a longer body for easier access during conventional and minimally invasive procedures...
Medicine Products: